Evotec SE

XETRA EVT.DE

Evotec SE Debt to Equity Ratio for the year ending December 31, 2023: 0.56

Evotec SE Debt to Equity Ratio is 0.56 for the year ending December 31, 2023, a 31.01% change year over year. Debt to equity ratio represents the financing from debt versus equity. Higher ratio indicates more debt reliance, suggesting potential risk.

Evotec SE Debt to Equity Ratio for the year ending December 31, 2022 was 0.43, a 14.63% change year over year.
Evotec SE Debt to Equity Ratio for the year ending December 31, 2021 was 0.37, a -45.30% change year over year.
Evotec SE Debt to Equity Ratio for the year ending December 31, 2020 was 0.68, a -29.89% change year over year.
Evotec SE Debt to Equity Ratio for the year ending December 31, 2019 was 0.97, a 259.61% change year over year.

Key data

Date	Debt to Equity Ratio	Debt to Income Ratio	Debt to Tangible Net Worth Ratio	Dividend Coverage Ratio

XETRA: EVT.DE

Evotec SE

CEO	Dr. Christian Wojczewski
IPO Date	Nov. 12, 1999
Location	Germany
Headquarters	Essener Bogen 7
Employees	5,007
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Key trends

Past 5 years